RECENT FUNDING
  1. Recent Funding
  2. Companies
  3. OMass Therapeutics

OMass Therapeutics

OMass Therapeutics is a drug discovery company exploiting novel mass spectrometry platforms to develop therapeutics.

Health and bio
Latest funding

$310M Series B+ ·

Led by Novo Holdings · Source: biotechtv.com

Total raised: $422.51M across 3 sourced rounds

All 4 rounds ↓
Website: omass.com.
X: @omasstx · 596 followers.
LinkedIn: linkedin.com.
Category: Health and bio.
Sectors: Biotechnology, Life Science, Pharmaceutical.
Stage: Series B+.
Based in: Oxford, United Kingdom.
Founded: 2016.
Total raised: $422.51M in 3 sourced rounds.
Last round: Oct 15, 2026 · 8 days ago.
Headcount: 11–50 employees.
X account age: 10 years.
Domain age: 13 years.
On Recent Funding since: Oct 16, 2026.
About OMass Therapeutics

OMass Therapeutics is a company based in Oxford, United Kingdom, founded in 2016. Recent Funding lists it under Health and bio. It raised $310M in a Series B+ round in October 2026, led by Novo Holdings, according to biotechtv.com. Recent Funding has 3 sourced rounds on record for it, totaling $422.51M, the first in April 2022. Investors on record include Bain Capital Life Sciences, British Patient Capital, Forbion Capital Partners, GV and 8 others. It was founded by Hsin-Yung Yen, Idlir Liko and Jonathan Hopper.

TIMELINE · MONEY RAISED

OMass Therapeutics | 1327 days from X account to first raise on record

@omasstx·Raised $423M in 3 sourced rounds·1 signal before the first raise
$106M$211M$317M$423MJULDECMAYOCTMARAUGJAN 2025JUN$423M||X ACCOUNT CREATED @OMASSTX · JUN 30, 2016Series A · Feb 17, 2020A · FEB '20$100M Series B+ · Apr 28, 2022$100M B+ · APR '22$12.51M Series B+ · May 15, 2023$12.51M B+ · MAY '23$310M Series B+ · Oct 15, 2026$310M B+ · OCT '26

Money raised, round by round (amounts linked to their source). Pins are dated signals; hover the icons for dates.

Funding rounds

  1. Series B+ · $310M
    NNovo Holdings (lead), GGV, JJanus Henderson Investors, JJefferson Life Sciences, NNorthpond Ventures, OOxford Science Enterprises, SSanofi Ventures, SSV Health Investors, SSyncona Partners LLP, UUniversity of Oxford
    Source: biotechtv.com
  2. Series B+ · $12.51M
    BBritish Patient Capital (lead)
    Source: lnkd.in
  3. Series B+ · $100M
    GGV (lead), NNorthpond Ventures (lead), SSanofi Ventures (lead), OOxford Science Enterprises, SSyncona Partners LLP, UUniversity of Oxford
    Source: omass.com
  4. Series A · amount undisclosed
    SSyncona Partners LLP (lead), OOxford Science Enterprises
    Source: innovation.ox.ac.uk
  5. X account created
  6. Website created

Founders and team

Investors

Similar Health and bio companies

Other companies backed by Novo Holdings

Novo Holdings portfolio →

Questions and sources

OMass Therapeutics: questions and answers

How much has OMass Therapeutics raised?
OMass Therapeutics has raised $422.51M across 3 sourced rounds on record. The latest is $310M (Series B+), announced October 15, 2026.
Who invested in OMass Therapeutics?
Investors on record for OMass Therapeutics: Bain Capital Life Sciences, British Patient Capital, Forbion Capital Partners, GV, Janus Henderson Investors, Jefferson Life Sciences, Northpond Ventures, Novo Holdings and 5 others. Novo Holdings led its latest sourced round.
Who founded OMass Therapeutics?
OMass Therapeutics was founded by Hsin-Yung Yen, Idlir Liko and Jonathan Hopper.
Where is OMass Therapeutics based?
OMass Therapeutics is based in Oxford, United Kingdom and was founded in 2016.

Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/omass-therapeutics (get a free API key).

Top raises, every week

The week's top funded startups and market insights, in your inbox every Monday.

Unsubscribe anytime · privacy